ORIGINAL RESEARCH article
Front. Nutr.
Sec. Nutritional Epidemiology
This article is part of the Research TopicNutrition-Related Clinical Laboratory Indicators: Enhancing Precision Medicine in Disease ManagementView all 4 articles
The Lactate-to-Albumin Ratio as a potential Biomarker for Short-Term Mortality Risk in Critically Ill Patients with Urosepsis: A Retrospective Study with Dual-Cohort Validation
Provisionally accepted- Zhejiang Provincial People's Hospital Bijie Hospital, Bijie, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The lactate-to-albumin ratio (LAR) comprehensively reflects the nutritional status, inflammatory level, and degree of oxidative stress in critically ill patients and has been demonstrated to be associated with poor prognosis in various critical illnesses. However, its prognostic role in the specific context of urosepsis remains to be fully elucidated. Methods: This study utilized the Medical Information Mart for Intensive Care (MIMIC-IV) database as an internal discovery cohort and included an external validation cohort from Bijie Hospital of Zhejiang Provincial People's Hospital. Multivariable Cox regression, restricted cubic splines (RCS), Kaplan-Meier survival curves, and other methods were employed to analyze the association between LAR and short-term adverse outcomes in urosepsis patients. The robustness of the findings was assessed through subgroup analysis and interaction tests. Furthermore, four machine learning algorithms were combined to screen key variables for constructing a multivariable Cox risk prediction model, the performance of which was evaluated using receiver operating characteristic (ROC) curves. Results: A total of 1,055 urosepsis patients were included. The 28-day ICU mortality and in-hospital mortality rates were 20.6% and 19.1%, respectively. After multivariable adjustment, for each unit increase in LAR as a continuous variable, the hazard ratios (HR) for ICU mortality and in-hospital mortality were 1.35 (95% CI: 1.08–1.68) and 1.50 (95% CI: 1.19–1.90), respectively. When treated as a categorical variable, the high LAR group had a 73% increased risk of ICU mortality and a 71% increased risk of in-hospital mortality compared to the low LAR group. RCS analysis revealed a non-linear positive dose-response relationship between LAR and mortality. ROC analysis demonstrated that a simple risk model incorporating LAR and five other variables had superior predictive performance compared to traditional critical illness scores, and these conclusions were consistently validated in the external cohort. Conclusion: The LAR is a cost-effective supplementary predictor of short-term mortality risk in critically ill urosepsis patients, primarily aiding early identification of high-risk cases to intensify monitoring and treatment. Its clinical value require further prospective validation.
Keywords: Adverse prognosis, biomarker, Lactate-to-albumin ratio (LAR), risk stratification, Urosepsis
Received: 24 Nov 2025; Accepted: 21 Jan 2026.
Copyright: © 2026 Nie, He, Wang, Zhu, Zhang, Hu and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ying Yu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
